JNJ 88998377
Alternative Names: JNJ-88998377Latest Information Update: 18 Jul 2024
At a glance
- Originator Janssen Research & Development
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-Hodgkin's lymphoma
Most Recent Events
- 28 May 2024 Phase-I clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater) in Turkey (PO) (NCT06470438)